First-in-Human trial tests 'Living Drug' for tough autoimmune cases
NCT ID NCT07331272
Summary
This is an early safety study to test a new type of treatment called LUCAR-G79D, a CAR-T cell therapy, in adults with severe lupus or inflammatory muscle disease that has not responded to other treatments. The main goal is to see if the treatment is safe, how the body handles it, and to find the right dose. Researchers will also check if it helps control disease symptoms over one year of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanfang Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Nanchang University
NOT_YET_RECRUITINGNanchang, Jiangxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third The People's Hospital of Bengbu
RECRUITINGBengbu, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.